Ranbaxy, Dr Reddy’s to benefit from tax sops - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Ranbaxy, Dr Reddy’s to benefit from tax sops

May 4, 2000

The government has granted full tax exemption (for a period of ten years) for inflows from milestone payments received by pharmaceutical companies on the sale of New Chemical Entities (NCE) and Novel Drug Delivery Systems (NDDS). This exemption currently stands at 50% of the payments received. Besides, the existing tax benefit of 125% of expenditure on R&D has been increased to 150%. This will further serve as a major incentive to the domestic pharma companies to invest in research as the cumulative tax benefit on such investments amounts to 57.75% (Corporate tax rate – 38.5% factored 1.50 times amounts to 57.75%).

Since the multinational companies do not carry out research in the country it will be the domestic pharmaceutical companies who will benefit from this move. Notable among these are Ranbaxy and Dr Reddy’s Laboratories (DRL).

Ranbaxy, for instance, received US $ 10 m (Rs 435 m) last year when it signed the deal with Bayer. Over the next 24–30 months the company would receive another $ 50 m (Rs 2,175 m) apart from a royalty of 10% on the sales of the new dosage form by Bayer. All these incomes would be tax–free.

Similarly, DRL has three new original molecules in its research pipeline. One is an anti–cancer compound, another was a Cox II inhibitor (anti–pain) and third was a compound indicated for metabolic disorders. The company foresees licensing out two of these to MNCs for clinical trials in the near future.

Any deal DRL enters into is likely to be modeled along the lines it has with the Danish company Novo Nordisk which is developing DRL’s diabetes lead molecules. The company is also working on a new class of diabetes products called PPAR, expected to have considerable potential.

Notable among the other beneficiaries are Cipla, Sun Pharma and Nicholas Piramal, which also have aggressive plans in the NCE segment.

Equitymaster requests your view! Post a comment on "Ranbaxy, Dr Reddy’s to benefit from tax sops". Click here!

  

More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS